Endocr. J./ R. YAMAMOTO-HONDA et al.: BLOOD GLUCOSE AND HbA1c LEVELS IN DIABETIC PATIENTS doi: /endocrj.K08E-071

Size: px
Start display at page:

Download "Endocr. J./ R. YAMAMOTO-HONDA et al.: BLOOD GLUCOSE AND HbA1c LEVELS IN DIABETIC PATIENTS doi: /endocrj.K08E-071"

Transcription

1 ORIGINAL Distribution of Blood Glucose and the Correlation between Blood Glucose and Hemoglobin A1c Levels in Diabetic Outpatients Ritsuko YAMAMOTO-HONDA 1, Hiroji KITAZATO 1, Shinji HASHIMOTO 2, Yoshihiko TAKAHASHI 3, Yoko YOSHIDA 1, Chiyoko HASEGAWA 1, Yasuo AKANUMA 1 and Mitsuhiko NODA 1,3 1 Department of Endocrinology and Metabolism, Marunouchi Hospital attached to the Institute for Adult Diseases, Asahi Life Foundation, 1-6-1, Marunouchi, Chiyoda-ku, Tokyo, , Japan 2 Research Management Department, Sanwa Kagaku Kennkyusho Co., Ltd., 363 Shiosaki, Hokusei, Inabe, Mie, , Japan 3 Department of Diabetes and Metabolic Medicine, International Medical Center of Japan, , Toyama, Shinjuku-ku, Tokyo, , Japan Received March 8, 2008; Accepted June 12, 2008; Released online July 9, 2008 Correspondence to: Mitsuhiko Noda, Department of Diabetes and Metabolic Medicine, International Medical Center of Japan, , Toyama, Shinjuku-ku, Tokyo, , Japan Abstract. Purpose of the study: Tight glycemic control is important for the prevention of microvascular complications in diabetic patients. We examined the reliability of using blood glucose levels measured at various time-points relative to a meal as an index of glycemic control in Japanese diabetic outpatients. Basic procedures followed: We examined the correlation between the fasting blood glucose (FBG) level; the one-hour (1-h), two-hour (2-h), and three-hour (3-h) post breakfast blood glucose (PBBG) levels, the 1h, 2h, and 3h post lunch blood glucose (PLBG) levels and the hemoglobin A1c levels in Japanese diabetic outpatients. A total of patient-visits to the Marunouchi Hospital between January 2002 and December 2002 were included in the study. The main findings: The blood glucose levels measured at all of the above time-points were significantly correlated with the HbA1c level. As calculated using local polynomial regression fitting, the FPG, 1-h, 2-h, and 3-h PBBG levels that corresponded to an HbA1c level of 6.5% were 132 mg/dl, 174 mg/dl, 170 mg/dl, and 143 mg/dl, respectively. The FPG and 2-h PBBG levels exhibited a good sensitivity and specificity for predicting a glycemic control corresponding to an HbA1c <5.8%, while the FPG and 3-h PBBG levels exhibited fair sensitivity and specificity for predicting glycemic control corresponding to an HbA1c <6.5%. The principal conclusions: The FBG, 2-hPBBG, and 3-hPBBG levels can be used as rough estimates of glycemic control in Japanese diabetic outpatients. Key words: diabetes, blood glucose, HbA1c TIGHT glycemic control is important for preventing microvascular complications in diabetic patients [1-3]. HbA1c is an established marker of long-term glycemic control in patients with diabetes. The UKPDS and DCCT demonstrated a significant association between HbA1c levels and the risk of occurrence of microvascular complications [3,4]. In addition, persistent postprandial hyperglycemia as well as an elevation of HbA1c has been linked to the risk of atherosclerotic diseases [5,6]. Numerous reports have suggested a good correlation between the HbA1c level and the fasting blood glucose level [7,8]. Nevertheless, the diagnostic value of postprandial blood glucose levels for estimating the HbA1c level in diabetic patients remains controversial [9]. In the present study, we analyzed the blood glucose levels (measured at various time-points relative to a meal) and the HbA1c levels in a large number of patients 1

2 and then examined the reliability of using these blood glucose levels measured at arbitrary time-points relative to a meal to estimate the HbA1c levels. Materials and Methods We retrospectively analyzed the charts of outpatients attending the Marunouchi Hospital attached to the Institute for Adult Disease, Asahi Life Foundation (located in the center of Tokyo) between January 2002 and December Patients with diabetes or impaired glucose tolerance were asked about the timing of their previous meal and their capillary blood was drawn to determine the blood glucose and HbA1c levels. The medical technologist judged the postprandial interval time and described it in 15-minute units. Among the records, we selected the blood glucose and HbA1c levels that were determined before breakfast, one hour after breakfast, two hours after breakfast, three hours after breakfast, one hour after lunch, two hours after lunch and three hours after lunch. A total of patient-visits made by 4120 patients (9334 patient-visits made by men and 2117 patient-visits made by women) were enrolled in the study. The mean (± standard deviation) age of the 4120 enrolled patients was 62.7 (±10.4) years, and the median, 25th percentile, and 75th percentile values of HbA1c were 6.6%, 5.9%, and 7.4%, respectively; and the duration of treatment for diabetes at the hospital was years (median, 8.9 years). Of the 4120 patients, 259 and 279 were diagnosed as having type 1 diabetes and impaired glucose tolerance, respectively. Treatment consisted of lifestyle intervention only in 21.1% of the patient-visits, sulfonylureas in 27.4%, a combination of sulfonylureas and biguanides in 12.7%, a combination of sulfonylureas and alpha-glucosidase inhibitors in 2.8%, combinations of other oral hypoglycemic agents in 4.4%, insulin only in 21.1%, a combination of insulin and sulfonylureas in 6.1%, a combination of insulin, sulfonylureas, and biguanides in 2.3%, and combinations of insulin and other oral hypoglycemic agents in 2.1%. Less than 0.2% of the patients were treated with the single use of nateglinide, biguanides, alpha-glucosidase inhibitors, or pioglitazone. The capillary blood glucose values were measured by the glucose-oxidase method (Fuji DRY-CHEM 300). The HbA1c values were measured using high-performance liquid chromatography (HLC-723 GHb V, Tosoh, Tokyo; the reference mean HbA1c value in non-diabetic subjects was 4.7%) [10]. Standard procedures were used to calculate the median, mean, SD and SEM. The relations between the HbA1c levels and the blood glucose levels were analyzed using linear regression according to the least squares method, non-parametric linear regression according to the method of Bablok et al. [11], and polynomial regression fitting according to locally weighted regression (loess {stats}, provided by R [12]). Correlations were calculated using Spearman s correlation coefficient. Statistical significance was considered to exist at the 5% level. Two-by-two contingency tables were formed for various cutoff points to examine the performance characteristics of the blood glucose levels for defining the sensitivity and specificity of the diagnostic test. The data were summarized using receiver-operating characteristic (ROC) curves. All the data was analyzed by R [12]. Glycemic control was categorized in accordance with the criteria of the Japan Diabetes Society as follows: HbA1c <5.8% (excellent), 5.8% HbA1c <6.5% (good), 6.5% HbA1c <8.0% (fair), and 8.0% HbA1c (poor) [13]. Results The distribution of the blood glucose levels is presented in Figure 1. Figure 2 shows the relations between the HbA1c and blood glucose levels at different time-points of measurement in the outpatients. There was a strong correlation between the HbA1c levels and the FBG levels. There were also good correlations between the HbA1c levels and the 1-hour postbreakfast blood glucose (1-h PBBG) level, the 2-hour postbreakfast blood 2

3 glucose (2-h PBBG) level, the 3-hour postbreakfast blood glucose (3-h PBBG), the 1-hour postlunch blood glucose (1-h PLBG) level, the 2-hour postlunch blood glucose (2-h PLBG) level, and the 3-hour postlunch blood glucose (3-h PLBG) level; all of the correlations were highly significant. Regression analyses (linear regression by the least squares method, linear regression by Bablok et al. [11], and polynomial regression fitting (loess)) produced very similar results (Fig. 2). Median blood glucose levels at each time-point corresponding to the various HbA1c levels, as determined by loess are presented in Table 1. The fasting blood glucose, 1-h PBBG, 2-h PBBG, 3-h PBBG, 1-h PLBG, 2-h PLBG and 3-h PLBG levels corresponding to an HbA1c level of 6.5% (associated with a minimal risk of the development of microvascular complications [13,14]) were 132 mg/dl, 174 mg/dl, 170 mg/dl, 143 mg/dl, 169 mg/dl, 170 mg/dl and 157 mg/dl, respectively. The difference between 2-h postprandial blood glucose levels and 1-h postprandial blood glucose levels corresponding to a given HbA1c value were very small when the HbA1c value was above 6.5%. The differences among postprandial blood glucose values corresponding to an HbA1c level of 5.8% were larger than those among postprandial blood glucose values corresponding to an HbA1c level of 8.0%. The 1-h PBBG, 1-h PLBG, 2-h PBBG, 2-h PLBG and 3-h PLBG levels corresponding to an HbA1c level of 8.0% were indistinguishable. Blood glucose levels corresponding to an HbA1c level of 6.5% as obtained using the loess tended to be higher in men than in women (Table 2) and tended to be slightly higher after lunch in patients younger than 60 years old (Table 3). The sensitivity and specificity of the blood glucose levels examined at various time-points to predict glycemic control corresponding to HbA1c levels of <5.8%, <6.5% and <8.0% were calculated and are plotted in Figure 3. The sensitivity and specificity to predict an HbA1c level of <5.8% and an HbA1c level of <8.0% were superior to those for predicting an HbA1c level of <6.5% (Table 5). The sensitivity and specificity of blood glucose levels measured before breakfast were good, while the specificity of 1-h PLBG levels were poor. To predict glycemic control corresponding to an HbA1c level of <5.8%, the sensitivity and specificity of the 2-h PBBG value were superior to those of the 1-h PBBG, 3-h PBBG and 3-h PLBG values. To predict glycemic control corresponding to an HbA1c level of <8.0%, the sensitivity and specificity of the 1-h PBBG, 3-h PBBG and 3-h PLBG values were superior to those of the 2-h PBBG. To predict glycemic control corresponding to an HbA1c level of <6.5%, the sensitivity, specificity and positive predictive value of FPG <130 mg/dl were 71.5%, 72.4% and 66.2%, whereas those of 2-h PBBG <170 mg/dl were 67.2%, 70.0% and 61.0%, respectively. When the data were categorized according to the treatment regimen (with neither oral hypoglycemic agents nor insulin, with oral hypoglycemic agents only, or with insulin), the correlation between the HbA1c and blood glucose levels was the strongest in patients not on medication and weakest in patients treated with insulin (Table 4). Two-hour post-breakfast glucose levels and HbA1c levels obtained from patients treated with various treatment regimens are presented in Figure 4. When the HbA1c levels was larger than 7.0%, the 2-h PBBG levels obtained from patients treated with sulfonylureas or sulfonylureas plus biguanides were lower than those obtained from patients treated with lifestyle intervention only. Data obtained from patients treated with insulin lispro or insulin aspart plus NPH insulin for a given HbA1c level exhibited lower 2-h PBBG values than those of patients treated with regular insulin plus NPH insulin. Discussion In the present study, by analyzing a large number of values of blood glucose and HbA1c, we attempted to determine the degree of reliability with which blood glucose 3

4 levels measured at various time-points relative to a meal could be used as an index of glycemic control in Japanese diabetic outpatients. Many reports have discussed the correlation between blood glucose and HbA1c levels. In type 2 diabetes, studies have shown that postprandial glucose levels measured at 1 h and 2 h after an oral glucose load or a test meal were correlated with the HbA 1c as closely as, or sometimes even more closely than, the fasting plasma glucose levels [15,16]. Kosaka reported that blood glucose levels measured 90 to 150 min after breakfast were well correlated with the HbA 1c [17]. In the present study, we confirmed the correlations between blood glucose values measured at various time-points relative to a meal and the HbA1c levels. We present the reference blood glucose levels measured at various time-points relative to a meal for a given HbA1c level. The estimated levels were very similar to the median blood glucose values shown in Figure 1, and the mean levels calculated from a primary approximation calculated using the least squares method or a linear regression analysis according to the method of Bablok et al. (Fig. 2). Blood glucose levels corresponding to an HbA1c level of 6.5% as obtained from a locally weighted regression tended to be slightly higher after lunch in patients younger than 60 years old (Table 3). The difference between <60 and 60 might be dependent on lifestyle-related differences between relatively younger and elder generations. Blood glucose levels corresponding to an HbA1c level of 6.5% as obtained using a locally weighed regression tended to be higher in men than in women (Table 2). Only a few reports have discussed differences in blood glucose levels between men and women. The gender differences have been reported not to affect the relation between blood glucose and HbA1c levels in the population of the United States [16]. The blood glucose profile after oral glucose load has been reported to vary according to gender in Chinese and Japanese subjects but not in Indian subjects [18]. Thus our present observation needs to be reexamined in other cohorts in Japan. Recently, persistent postprandial hyperglycemia has been suggested to be associated with a risk of atherosclerotic diseases [5,6]. We therefore attempted to examine the difference in 2-hPBBG values for a given HbA1c level according to the various treatment regimens. In the present study, the number of patients receiving monotherapy of alpha-glucosidase inhibitors, nateglinide, or pioglitazone or combination therapy with sulfonylureas and alpha-glucosidase inhibitors was too small for the effect of these drugs on postprandial blood glucose patterns to be analyzed. Treatment with insulin aspart or insulin lispro with NPH insulin is known to lower postprandial blood glucose more than combination therapy with regular insulin and NPH insulin [19,20]. This result was reproducible with our present analysis (Fig. 4). The correlation between the value of blood glucose and HbA1c level is well known and an excellent relation between the HbA1c level and the mean glucose levels measured by continuous glucose monitoring was recently reported by Nathan et al. [21]. In clinical practice, whether the fasting blood glucose value or the postprandial blood glucose value is a better predictor of HbA1c level remains controversial. Avignon et al. reported the prebreakfast (8:00 A.M.), prelunch (11:00 A.M.), postlunch (2:00 P.M.) and extended postlunch (5:00 P.M.) plasma glucose levels in type 2 diabetic patients were all significantly correlated with the HbA1c level. They pointed out that the postlunch and extended postlunch plasma glucose levels exhibited a better sensitivity and specificity for predicting an HbA1c value of 8.5% than the prebreakfast plasma glucose level [9]. In contrast, Bonora et al. reported that HbA 1c level was more strongly correlated with the preprandial blood glucose level than the postprandial (2-3 h after a meal) blood glucose level [8]. Pistrosch et al. examined the relationship between HbA1c and blood glucose levels measured at various times. They reported that the pre-breakfast blood glucose level showed the strongest correlation with the HbA1c level [22]. 4

5 As shown in Figure 1, a given value of blood glucose was distributed over such a wide range of HbA1c levels that the prediction of HbA1c from a given blood glucose level was done at a cost of more than 24% false positives and more than 24% false negatives (Fig. 3). At best, the FBG levels exhibited a fair sensitivity and specificity throughout the range of HbA1c levels that were examined. The sensitivity and specificity of various postprandial levels for predicting a given HbA1c level varied with the target HbA1c. To predict an HbA1c level of <5.8%, the 2-h PBBG level, but not the 2-h PLBG level, appeared to have an equal specificity and sensitivity to those of the FBG level. This situation resembles the good specificity and sensitivity of the 2-h post glucose load value for diagnosing diabetes mellitus. However, the 2-h PBBG value did not show a satisfactory specificity or sensitivity for predicting an HbA1c level of <6.5% or <8.0%. In summary, by examining the blood glucose and HbA1c levels of diabetic patients during routine visits to the diabetic clinic, we attempted to ascertain the correlation between HbA1c and the blood glucose levels measured at various time-points relative to a meal, and presented the resulting data to help estimate the HbA1c using the clinical examination of blood glucose levels. The FBG and 2-h PBBG levels exhibited a fair sensitivity and specificity for predicting an excellent glycemic control. The values of FBG and those of 3-h PBBG exhibited fair sensitivity and specificity in predicting fair glycemic control. These data enable a basic understanding of the relation between postprandial blood glucose levels and HbA1c in diabetic outpatients. Acknowledgments We thank Ms. Kumiko Kimura and Ms. Tomoyo Sato for their excellent technical assistance. References 1. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 28: The Diabetes Control and Complications Trial (DCCT) Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS33. Lancet 352: Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN; DCCT/EDIC Research Group (2008). The effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial revisited. Diabetes 57: DECODE Study Group, the European Diabetes Epidemiology Group (2001). Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161: Nakagami T; DECODA Study Group (2004) Hyperglycemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 47: Bouma M, Dekker JH, De Sonnaville JJ, van der Does FE, de Vries H, Kriegsman DM, Kostense PJ, Heine RJ, van Eijk JT (1999) How valid is fasting plasma glucose 5

6 as a parameter of glycemic control in non-insulin-using patients with type 2 diabetes? Diabetes Care 22: Bonora E, Calcaterra F, Lombardi S, Bonfante N, Formentini G, Bonadonna RC, Muggeo M (2001) Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care 24: Avignon A, Radauceanu A, Monnier L (1997) Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20: Tominaga M, Makino H, Yoshino G, Kuwa K, Takei I, Aono Y, Hoshino T, Umemoto M, Shimatsu A, Sanke T, Kuwashima M, Taminato T, Ono J (2005) Japanese standard reference material for JDS Lot 2 haemoglobin A1c. I: Comparison of Japan Diabetes Society-assigned values to those obtained by the Japanese and USA domestic standardization programmes and by the International Federation of Clinical Chemistry reference laboratories. Ann Clin Biochem. 42 (Pt 1): Bablok W, Passing H, Bender R, Schneider B (1988) A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J. Clin. Chem. Clin. Biochem. 26: Ihaka R and Gentleman R (1996) R: a language for data analysis and graphics. J. Comp. Graph. Stat. 5: Available via Japan Diabetes Society (eds.) (2007) Glycemic control indicators and assessment. In Treatment guide for diabetes. Bunkodo: Tokyo, p International Diabetes Federation (eds) (2005) Glucose control levels. In Global guideline for type 2 diabetes. International Diabetes Federation, p Monnier L, Lapinski H, Colette C (2003) Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1 (c). Diabetes Care 26: Woerle HJ, Pimenta WP, Meyer C, Gosmanov NR, Szoke E, Szombathy T, Mitrakou A, Gerichc JE (2004) Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1C values. Arch Intern Med 164: Kosaka K (1997) Parameters used for the diagnosis and screening of diabetes mellitus and their mutual relationships. Nippon Rinsho 55 (725): [Article in Japanese] 18. The DECODA Study Group (2003) Age- and sex- specific prevalence of diabetes and impaired glucose regulation in 11 Asian cohorts. Diabetes Care 26: Pampanelli S, Torlone E, Ialli C, Del Sindaco P, Ciofetta M, Lepore M, Bartocci L, Brunetti P, Bolli GB (1995) Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function. Diabetes Care 18: Rosenfalck AM, Thorby P, Kjems L, Dejgaard A, Hanssen KF, Madbad S (2000) Improved postprandial gylcemic control with insulin Aspart in type 2 diabetic patients treated with insulin. Acta Diabetol. 37: Nathan DM, Turgeon H, Regan S (2007) Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 50: Pistrosch F, Koehler C, Wildbrett J, Hanefeld M (2006). Relationship between diurnal glucose levels and HbA1c in type 2 diabetes. Horm Metab Res 38:

7 Fig. 1. Distribution of fasting and postprandial blood glucose levels according to HbA1c levels. 7

8 Fig. 2. Relation between the HbA1c values and blood glucose values. Red line indicates the linear regression according to the least squares method. Yellow line indicates the linear regression according to the method of Bablok et al. [11]. Green line indicates the locally weighted regression line (loess). 8

9 Fig. 3. Receiver-operating characteristic (ROC) curves for predicting glycemic control corresponding to HbA1c levels of <5.8%, <6.5% and <8.0% based on the blood glucose measurement. 9

10 Fig. 4. Relation between HbA1c values and blood glucose values measured 2 h after breakfast; categorized according to diabetic treatment regimen. Samples were taken from patients with the fixed treatment regimen throughout the examination period. Lines indicate the locally weighted regression line (loess). 10

11 Table 1. Blood glucose values corresponding to HbA1c values of 5.8%, 6.5%, and 8.0% Time of examination Values corresponding to an HbA1c value of 5.8% Values corresponding to an HbA1c value of 6.5% Values corresponding to an HbA1c value of 8.0% Fasting 120 mg/dl 132 mg/dl 159 mg/dl One hour after breakfast 160 mg/dl 174mg/dL 208 mg/dl Two hours after breakfast 146 mg/dl 170 mg/dl 201 mg/dl Three hour after breakfast 123 mg/dl 143 mg/dl 182 mg/dl One hour after lunch 159 mg/dl 169 mg/dl 197 mg/dl Two hours after lunch 151 mg/dl 170 mg/dl 199 mg/dl Three hours after lunch 138 mg/dl 157 mg/dl 196 mg/dl Table 2. Relationship between the HbA1c values and blood glucose values according to gender Time of examination Fasting One hour after breakfast Two hours after breakfast Three hours after breakfast One hour after lunch Two hours after lunch Three hours after lunch Gender of the patients Number of patient-visits Median value of HbA1c (%) R Blood glucose values (mg/dl) corresponding to an HbA1c level of 6.5% men women * 122 men women men women ** 153 men women men women men women men women * 135 ** p < 0.01, * p < 0.05 versus R value of men. 11

12 Table 3. Relationship between the HbA1c values and blood glucose values according to patient age Time of examination Fasting Age of patients (years) Number of patient-visits Median value of HbA1c (%) R Blood glucose values (mg/dl) corresponding to an HbA1c level of 6.5% < ** 130 One hour after < breakfast Two hours after < breakfast Three hours < after breakfast ** 144 One hour after < lunch Two hours after < lunch Three hours < after lunch ** p < 0.01 versus R value of patients under 60 years old. 12

13 Table 4. Correlation between the HbA1c values and blood glucose values according to diabetic treatment regimen Timing of examination Medication for hyperglycemia Number of patient-visits Median value of HbA1c (%) R Blood glucose values (mg/dl) corresponding to an HbA1c level of 6.5% Fasting One hour after breakfast Two hours after breakfast Three hours after breakfast One hour after lunch Two hours after lunch Three hours after lunch None OHA *** 138 Insulin *** 125 None OHA Insulin None OHA *** 172 Insulin *** 169 None OHA Insulin *** 149 None OHA Insulin None OHA Insulin ** 166 None OHA Insulin *** p < 0.001, ** p < 0.01 versus R value of patients without medication for hyperglycemia. OHA: oral hypoglycemic agents. 13

14 Table 5. Values obtained from the receiver-operating characteristic curves for estimating the HbA1c levels from the blood glucose values Target HbA1c Level (%) < 5.8% < 6.5% < 8.0% Timing of examination PB: post breakfast PL: post lunch Value of blood glucose (mg/dl) with equal sensitivity and specificity (a) Sensitivity (=specificity) values corresponding to blood glucose values of (a) Value of blood glucose (mg/dl) with the maximum sensitivity + specificity (b) Sensitivity + specificity values corresponding to blood glucose values of (b) Fasting One hour PB Two hours PB Three hours PB One hour PL Two hours PL Three hours PL Fasting One hour PB Two hours PB Three hours PB One hour PL Two hours PL Three hours PL Fasting One hour PB Two hours PB Three hours PB One hour PL Two hours PL Three hours PL PB: post breakfast, PL: post lunch. 14

Use of Insulin Glargine in Japanese Patients with Type 1 Diabetes

Use of Insulin Glargine in Japanese Patients with Type 1 Diabetes ORIGINAL ARTICLE Use of Insulin Glargine in Japanese Patients with Type 1 Diabetes Ritsuko Yamamoto-Honda 1, Yoshihiko Takahashi 2, Yoko Yoshida 1,YokoHara 1, Atsuo Kawai 1, Hiroji Kitazato 1, Takahisa

More information

Comprehensive Diabetes Treatment

Comprehensive Diabetes Treatment Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes

More information

Improvement of glycemic control and quality-of-life by insulin lispro therapy: Assessing benefits by ITR-QOL questionnaires

Improvement of glycemic control and quality-of-life by insulin lispro therapy: Assessing benefits by ITR-QOL questionnaires diabetes research and clinical practice 81 (2008) 169 178 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/diabres Improvement of glycemic control and quality-of-life by insulin

More information

Body Mass Index, Fasting Plasma Glucose Levels, and C-peptide Levels as Predictors of the Future Insulin Use in Japanese Type 2 Diabetic Patients

Body Mass Index, Fasting Plasma Glucose Levels, and C-peptide Levels as Predictors of the Future Insulin Use in Japanese Type 2 Diabetic Patients Endocrine Journal 2010, 57 (3), 237-244 Or i g i n a l Body Mass Index, Fasting Plasma Glucose Levels, and C-peptide Levels as Predictors of the Future Insulin Use in Japanese Type 2 Diabetic Patients

More information

Evaluating Once- and Twice-Daily Self- Monitored Blood Glucose Testing Strategies for Stable Insulin-Treated Patients With Type 2 Diabetes

Evaluating Once- and Twice-Daily Self- Monitored Blood Glucose Testing Strategies for Stable Insulin-Treated Patients With Type 2 Diabetes Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Evaluating Once- and Twice-Daily Self- Monitored Blood Glucose Testing Strategies for Stable Insulin-Treated Patients With

More information

Diabetes Mellitus Type 2 Evidence-Based Drivers

Diabetes Mellitus Type 2 Evidence-Based Drivers This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose

More information

Correlation between baseline serum 1,5-anhydroglucitol levels and 2-hour post-challenge glucose levels during oral glucose tolerance tests

Correlation between baseline serum 1,5-anhydroglucitol levels and 2-hour post-challenge glucose levels during oral glucose tolerance tests Endocrine Journal 2011, 58 (1), 13-17 Or i g i n a l Correlation between baseline serum 1,5-anhydroglucitol levels and 2-hour post-challenge glucose levels during oral glucose tolerance tests Maki Goto

More information

Early diagnosis, early treatment and the new diagnostic criteria of diabetes mellitus

Early diagnosis, early treatment and the new diagnostic criteria of diabetes mellitus British Journal of Nutrition (2000), 84, Suppl. 2, S177±S181 S177 Early diagnosis, early treatment and the new diagnostic criteria of diabetes mellitus Takeshi Kuzuya* JA Shioya General Hospital, Tomita

More information

Possible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other diseases

Possible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other diseases Clin Exp Nephrol (2015) 19:1179 1183 DOI 10.1007/s10157-015-1110-6 ORIGINAL ARTICLE Possible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other

More information

New treatment regimens and guidelines have

New treatment regimens and guidelines have ORIGINAL ARTICLE Associations Between Features of Glucose Exposure and A1C The A1C-Derived Average Glucose (ADAG) Study Rikke Borg, 1 Judith C. Kuenen, 2 Bendix Carstensen, 1 Hui Zheng, 3 David M. Nathan,

More information

Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control

Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control can prevent many of early type 1 DM(in DCCT trail ). UK

More information

Diabetes is a metabolic disorder primarily

Diabetes is a metabolic disorder primarily P O S I T I O N S T A T E M E N T Implications of the United Kingdom Prospective Diabetes Study AMERICAN DIABETES ASSOCIATION Diabetes is a metabolic disorder primarily characterized by elevated blood

More information

Diabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE

Diabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized

More information

Timely!Insulinization In!Type!2! Diabetes,!When!and!How

Timely!Insulinization In!Type!2! Diabetes,!When!and!How Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for

More information

Strict glycemic control in patients with diabetes decreases

Strict glycemic control in patients with diabetes decreases Glycated Albumin Is a Better Glycemic Indicator than Glycated Hemoglobin Values in Hemodialysis Patients with Diabetes: Effect of Anemia and Erythropoietin Injection Masaaki Inaba,* Senji Okuno, Yasuro

More information

Diabetes Care 25: , 2002

Diabetes Care 25: , 2002 Pathophysiology/Complications O R I G I N A L A R T I C L E The Glucose Area Under the Profiles Obtained With Continuous Glucose Monitoring System Relationships With HbA lc in Pediatric Type 1 Diabetic

More information

Guidelines for diabetes mellitus: from the perspective of diagnosis and treatment

Guidelines for diabetes mellitus: from the perspective of diagnosis and treatment REVIEW ARTICLES Guidelines for diabetes mellitus: from the perspective of diagnosis and treatment Tomoko Nakagami 1 Yasuko Uchigata 1 1 Diabetes Center, Tokyo Women s Medical University School of Medicine

More information

ORIGINAL INVESTIGATION

ORIGINAL INVESTIGATION ORIGINAL INVESTIGATION Diagnostic and Therapeutic Implications of Relationships Between Fasting, 2-Hour Postchallenge Plasma Glucose and Hemoglobin A 1c Values Hans J. Woerle, MD; Walkyria P. Pimenta,

More information

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification

Agenda. Indications Different insulin preparations Insulin initiation Insulin intensification Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations

More information

Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre

Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What

More information

INSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد

INSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid

More information

Moving to an A1C-Based Screening & Diagnosis of Diabetes. By Prof.M.Assy Diabetes&Endocrinology unit

Moving to an A1C-Based Screening & Diagnosis of Diabetes. By Prof.M.Assy Diabetes&Endocrinology unit Moving to an A1C-Based Screening & Diagnosis of Diabetes By Prof.M.Assy Diabetes&Endocrinology unit is the nonenzymatic glycated product of the hemoglobin beta-chain at the valine terminal residue. Clin

More information

ORIGINAL ARTICLE. Abstract. Introduction

ORIGINAL ARTICLE. Abstract. Introduction ORIGINAL ARTICLE Investigating the Relationship between Morning Glycemic Variability and Patient Characteristics Using Continuous Glucose Monitoring Data in Patients with Type 2 Diabetes Soichi Takeishi,

More information

Analysis for the Improvement of Inadequate Glycemic Control in Patients with Type 2 Diabetes Mellitus in Nagano, Japan

Analysis for the Improvement of Inadequate Glycemic Control in Patients with Type 2 Diabetes Mellitus in Nagano, Japan Shinshu Med J, 66⑸:319~324, 2018 Analysis for the Improvement of Inadequate Glycemic Control in Patients with Type 2 Diabetes Mellitus in Nagano, Japan Ai Sato 1 ), Yoshihiko Sato 1)*, Yuki Kobayashi 1)

More information

Sponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

Sponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

INSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital

INSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital INSULIN THERAPY Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 3 Sep. 2013 Case Somsak is a 64-year-old man was diagnosed with T2DM, HT, and dyslipidemia 9 years ago. No history of hypoglycemia

More information

Diabetes Care 25: , 2002

Diabetes Care 25: , 2002 Pathophysiology/Complications O R I G I N A L A R T I C L E Morning Hyperglycemic Excursions A constant failure in the metabolic control of non insulin-using patients with type 2 diabetes LOUIS MONNIER,

More information

Measuring Effectiveness of Glimepiride Titration Using SMBG in Patients with Mild Type 2 Diabetes

Measuring Effectiveness of Glimepiride Titration Using SMBG in Patients with Mild Type 2 Diabetes 38 The Open Diabetes Journal, 09, 2, 38-43 Open Access Measuring Effectiveness of Glimepiride Titration Using in Patients with Mild Type 2 Diabetes Akio Kanazawa,1, Tomoaki Shimizu 1, Chie Ebato 1, Yuko

More information

Initiation and Titration of Insulin in Diabetes Mellitus Type 2

Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.

More information

Diabetes Care 25: , role of sustained hyperglycemia in the development

Diabetes Care 25: , role of sustained hyperglycemia in the development Pathophysiology/Complications O R I G I N A L A R T I C L E Improved Postprandial Glycemic Control With Biphasic Insulin Aspart Relative to Biphasic Insulin Lispro and Biphasic Human Insulin in Patients

More information

Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes

Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes European Journal of Endocrinology (2006) 155 615 622 ISSN 0804-4643 CLINICAL STUDY Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes Wan Sub Shim, Soo Kyung

More information

Insulin Pump Therapy for Type 2

Insulin Pump Therapy for Type 2 9501172-011 Insulin Pump Therapy for Type 2 Objective To show the effectiveness of CSII for insulin-taking type 2 patients Key Points Tight glycemic control decreases risk of diabetes-related complications

More information

Major Increases between Pre- and Post-breakfast Glucose Levels May Predict Nocturnal Hypoglycemia in Type 2 Diabetes

Major Increases between Pre- and Post-breakfast Glucose Levels May Predict Nocturnal Hypoglycemia in Type 2 Diabetes ORIGINAL ARTICLE Major Increases between Pre- and Post-breakfast Glucose Levels May Predict Nocturnal Hypoglycemia in Type 2 Diabetes Soichi Takeishi, Akihiro Mori, Miyuka Kawai, Yohei Yoshida, Hiroki

More information

Type 1 diabetes, although the most common

Type 1 diabetes, although the most common ADDRESSING THE 21ST CENTURY DIABETES EPIDEMIC * Based on a presentation by David M. Nathan, MD ABSTRACT Type 2 diabetes is an epidemic disorder. Although its complications can be treated, prevented, or

More information

Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes

Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell

More information

Department of Health Planning Center, Nihon University Hospital, Tokyo Japan 2

Department of Health Planning Center, Nihon University Hospital, Tokyo Japan 2 94 Original Article Differences between Mitiglinide/Voglibose Fixeddose Combination and Glimepiride in Modifying Lowdensity Lipoprotein Heterogeneity in Japanese Type-2 Diabetic Patients: A Pilot Study

More information

Injecting Insulin into Out Patient Practice

Injecting Insulin into Out Patient Practice Injecting Insulin into Out Patient Practice Kathleen Colleran, MD Associate Professor UNMHSC 4/22/10 Overview Natural history of Type 2 diabetes Reasons clinicians are reluctant to start insulin therapy

More information

ORIGINAL ARTICLE. Abstract. Introduction

ORIGINAL ARTICLE. Abstract. Introduction ORIGINAL ARTICLE Effect of Switching from Sulphonylurea to Repaglinide Twice or Three Times Daily for 4 Months on Glycemic Control in Japanese Patients with Type 2 Diabetes Hiroshi Kamiyama 1, Kazutaka

More information

WILL YOU USE HBA1C TO SCREEN & MONITOR DIABETES? Dr. Amany Mousa

WILL YOU USE HBA1C TO SCREEN & MONITOR DIABETES? Dr. Amany Mousa WILL YOU USE HBA1C TO SCREEN & MONITOR DIABETES? Dr. Amany Mousa Diabetes is clinically well defined by glycation of proteins 1. True 2. false So far, diabetes has been defined as a clinical condition

More information

Evolving insulin therapy: Insulin replacement methods and the impact on cardiometabolic risk

Evolving insulin therapy: Insulin replacement methods and the impact on cardiometabolic risk Evolving insulin therapy: Insulin replacement methods and the impact on cardiometabolic risk Harvard/Joslin Primary Care Congress for Cardiometabolic Health 2013 Richard S. Beaser, MD Medical Executive

More information

Impact of Glycemic Control on Survival of Diabetic Patients on Chronic Regular Hemodialysis

Impact of Glycemic Control on Survival of Diabetic Patients on Chronic Regular Hemodialysis Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Impact of Glycemic Control on Survival of Diabetic Patients on Chronic Regular Hemodialysis A 7-year observational study TAKESHI OOMICHI,

More information

Sponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine)

Sponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Insulin Initiation and Intensification. Disclosure. Objectives

Insulin Initiation and Intensification. Disclosure. Objectives Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School

More information

Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus

Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus CLINICAL TRIAL Efficacy and safety of repaglinide vs nateglinide for treatment of Japanese patients with type 2 diabetes mellitus Ryuzo Kawamori 1 *, Kohei Kaku 2, Toshiaki Hanafusa 3, Daisuke Kashiwabara

More information

Insulin Intensification: A Patient-Centered Approach

Insulin Intensification: A Patient-Centered Approach MARTIN J. ABRAHAMSON, MD Harvard Medical School, Boston, MA Insulin Intensification: A Patient-Centered Approach Dr Abrahamson is associate professor of medicine at Harvard Medical School and medical director

More information

Managing Diabetes for Improved Health and Economic Outcomes

Managing Diabetes for Improved Health and Economic Outcomes Managing Diabetes for Improved Health and Economic Outcomes Based on a presentation by David McCulloch, MD Presentation Summary The contribution of postprandial glucose to diabetes progression and diabetes-related

More information

Glucose Control: Does it lower CV risk?

Glucose Control: Does it lower CV risk? Glucose Control: Does it lower CV risk? Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic,

More information

Utility of Casual Postprandial Glucose Levels in Type 2 Diabetes Management

Utility of Casual Postprandial Glucose Levels in Type 2 Diabetes Management Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Utility of Casual Postprandial Glucose Levels in Type 2 Diabetes Management IMAD M. EL-KEBBI, MD DAVID C. ZIEMER, MD CURTISS B. COOK, MD

More information

Update on Insulin-based Agents for T2D

Update on Insulin-based Agents for T2D Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment

More information

Addressing Addressing Challenges in Type 2 Challenges in Type 2 Diabetes Diabetes Speaker:

Addressing Addressing Challenges in Type 2 Challenges in Type 2 Diabetes Diabetes Speaker: Addressing Challenges in Type 2 Diabetes Geneva Briggs, PharmD,, BCPS Addressing Challenges in Type 2 Diabetes Speaker: Dr. Geneva Clark Briggs, a board-certified Pharmacotherapy Specialist, received her

More information

Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary

Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions

More information

Charles Darwin University

Charles Darwin University Charles Darwin University Area-under-the-HbA1c-curve above the normal range and the prediction of microvascular outcomes an analysis of data from the Diabetes Control and Complications Trial Maple-Brown,

More information

Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes

Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes REVIEW Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes Nazia Raja-Khan Sarah S Warehime Robert A Gabbay Division of Endocrinology, Diabetes, and Metabolism, Penn State Institute

More information

Open Access RESEARCH. Kazuhiro Eto 1*, Yusuke Naito 2 and Yutaka Seino 3

Open Access RESEARCH. Kazuhiro Eto 1*, Yusuke Naito 2 and Yutaka Seino 3 DOI 10.1186/s13098-015-0104-6 RESEARCH Evaluation of the efficacy and safety of lixisenatide add on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal

More information

UKPDS: Over Time, Need for Exogenous Insulin Increases

UKPDS: Over Time, Need for Exogenous Insulin Increases UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin

More information

Combined measurement of fasting plasma glucose and HbA1c is effective for the prediction of type 2 diabetes: The Kansai Healthcare Study

Combined measurement of fasting plasma glucose and HbA1c is effective for the prediction of type 2 diabetes: The Kansai Healthcare Study Diabetes Care Publish Ahead of Print, published online January 8, 2009 Combined measurement of fasting plasma glucose and HbA1c is effective for the prediction of type 2 diabetes: The Kansai Healthcare

More information

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:

ClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company: These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov

More information

Glucose and CV disease

Glucose and CV disease Glucose and CV disease Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,

More information

Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients

Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients ORIGINAL ARTICLE Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients Yukihiro Bando, Hideo Kanehara, Keiko Aoki, Azusa Hisada, Daisyu Toya, Nobuyoshi Tanaka

More information

nocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded

nocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded Clinical Trial Design/ Primary Objective Insulin glargine Treat-to-Target Trial, Riddle et al., 2003 (23) AT.LANTUS trial, Davies et al., 2005 (24) INSIGHT trial, Gerstein et al., 2006 (25) multicenter,

More information

Update on Insulin-based Agents for T2D. Harry Jiménez MD, FACE

Update on Insulin-based Agents for T2D. Harry Jiménez MD, FACE Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer

More information

Hitoshi Ishii & Eisei Oda

Hitoshi Ishii & Eisei Oda Reproducibility and validity of a satisfaction questionnaire on hypoglycemic agents: the Oral Hypoglycemic Agent Questionnaire (OHA-Q) Hitoshi Ishii & Eisei Oda Diabetology International ISSN 2190-1678

More information

Twenty-four-hour variations in blood glucose level in Japanese type 2 diabetes patients based on continuous glucose monitoring

Twenty-four-hour variations in blood glucose level in Japanese type 2 diabetes patients based on continuous glucose monitoring Twenty-four-hour variations in blood glucose level in Japanese type 2 diabetes patients based on continuous glucose monitoring Maiko Hajime, Yosuke Okada, Hiroko Mori, Takashi Otsuka, Mayuko Kawaguchi,

More information

Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville

Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis

More information

SCIENTIFIC STUDY REPORT

SCIENTIFIC STUDY REPORT PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established

More information

HBA1C AS A MARKER FOR HIGH RISK DIABETIC SURGICAL PATIENT

HBA1C AS A MARKER FOR HIGH RISK DIABETIC SURGICAL PATIENT Basrah Journal Of Surgery Bas J Surg, September, 18, 2012 HBA1C AS A MARKER FOR HIGH RISK DIABETIC SURGICAL PATIENT MB,ChB, DA, FICMS, Lecturer in Anesthesiology, Department of Surgery, College of Medicine,

More information

These results are supplied for informational purposes only.

These results are supplied for informational purposes only. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

Harvesting Healthy Hemogobins: Optimal Management of A1c and Beyond. Carol H. Wysham, M.D Rockwood Clinic Spokane, WA

Harvesting Healthy Hemogobins: Optimal Management of A1c and Beyond. Carol H. Wysham, M.D Rockwood Clinic Spokane, WA Harvesting Healthy Hemogobins: Optimal Management of A1c and Beyond Carol H. Wysham, M.D Rockwood Clinic Spokane, WA Diabetes: 21 Million and Climbing Estimated 15 million diagnosed + 6.2 million undiagnosed

More information

Implementation Conference for ACE Outpatient Diabetes Mellitus Consensus Conference Recommendations: Position Statement.

Implementation Conference for ACE Outpatient Diabetes Mellitus Consensus Conference Recommendations: Position Statement. Implementation Conference for ACE Outpatient Diabetes Mellitus Consensus Conference Recommendations: Position Statement February 2, 2005 Over 20 million Americans suffer from diabetes; approximately one

More information

Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes

Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes Imai et al. Diabetology & Metabolic Syndrome 2014, 6:110 DIABETOLOGY & METABOLIC SYNDROME RESEARCH Open Access Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2

More information

Comparison of thrice-daily lispro 50/50 vs thrice-daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes

Comparison of thrice-daily lispro 50/50 vs thrice-daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes ORIGINAL ARTICLE Comparison of thrice-daily lispro 50/50 vs thrice-daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes Keiko Yamashiro 1,FukiIkeda 1, Yoshio Fujitani

More information

Article: Epidemiology Haemoglobin A 1c cut-off point to identify a high risk group of future diabetes: results from the Omiya MA Cohort Study

Article: Epidemiology Haemoglobin A 1c cut-off point to identify a high risk group of future diabetes: results from the Omiya MA Cohort Study Article: Epidemiology Haemoglobin A 1c cut-off point to identify a high risk group of future diabetes: results from the Omiya MA Cohort Study M. Kato 1, M. Noda 2, H. Suga 3, T. Nakamura 3, M. Matsumoto

More information

Francesca Porcellati

Francesca Porcellati XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia

More information

Title. Study of Diabetes. Citation Journal Diabetologia, 50(1): Issue Date Journal Article. Text version author

Title. Study of Diabetes. Citation Journal Diabetologia, 50(1): Issue Date Journal Article. Text version author Title Author(s) Comment on: Nathan DM, Buse JB, Dav Management of hyperglycaemia in typ for the initiation and adjustment o the American Diabetes Association a Study of Diabetes. Takamura, Toshinari; Shimizu,

More information

Akio Ohta, Kaori Arai, Ami Nishine, Yoshiyuki Sada, Hiroyuki Kato, Hisashi Fukuda, Shiko Asai, Yoshio Nagai, Takuyuki Katabami and Yasushi Tanaka

Akio Ohta, Kaori Arai, Ami Nishine, Yoshiyuki Sada, Hiroyuki Kato, Hisashi Fukuda, Shiko Asai, Yoshio Nagai, Takuyuki Katabami and Yasushi Tanaka Endocrine Journal 2013, 60 (2), 173-177 Or i g i n a l Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial

More information

The MiniMed Continuous Glucose Monitoring System. JOHN J. MASTROTOTARO, Ph.D.

The MiniMed Continuous Glucose Monitoring System. JOHN J. MASTROTOTARO, Ph.D. DIABETES TECHNOLOGY & THERAPEUTICS Volume 2, Supplement 1, 2000 Mary Ann Liebert, Inc. The MiniMed Continuous Glucose Monitoring System JOHN J. MASTROTOTARO, Ph.D. DIABETES is a major source of morbidity,

More information

CE on SUNDAY Newark, NJ October 18, 2009

CE on SUNDAY Newark, NJ October 18, 2009 CE on SUNDAY Newark, NJ October 18, 2009 Date: Sunday, October 18, 2009 Time: 2:45 PM 3:45 PM Location: Sheraton Newark Airport Hotel Title: Speaker(s): Addressing Challenges in Type 2 Diabetes ACPE #

More information

Limitations of Conventional Methods of Self-Monitoring of Blood Glucose

Limitations of Conventional Methods of Self-Monitoring of Blood Glucose Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Limitations of Conventional Methods of Self-Monitoring of Blood Glucose Lessons learned from 3 days of continuous glucose sensing in pediatric

More information

Key words: Diabetes mellitus, fasting plasma glucose, oral glucose tolerance test, A1C

Key words: Diabetes mellitus, fasting plasma glucose, oral glucose tolerance test, A1C Diagnosis of Diabetes Mellitus and Pre-Diabetes with Fasting Plasma Glucose, Oral Glucose Tolerance Test and A1c Level: A1c Based Screening May Be A Better Diagnostic Tool For Diabetes Mellitus Mehmet

More information

An analysis of baseline data from the ORIGIN trial

An analysis of baseline data from the ORIGIN trial Epidemiology/Health Services Research O R I G I N A L A R T I C L E Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes An analysis of baseline data from the ORIGIN trial

More information

APPENDIX American Diabetes Association. Published online at

APPENDIX American Diabetes Association. Published online at APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no

More information

Clinical Overview of Combination Therapy with Sitagliptin and Metformin

Clinical Overview of Combination Therapy with Sitagliptin and Metformin Clinical Overview of Combination Therapy with Sitagliptin and Metformin 1 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy

More information

Type 2 Diabetes Mellitus 2011

Type 2 Diabetes Mellitus 2011 2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose

More information

The Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial -- Revisited

The Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial -- Revisited Diabetes Publish Ahead of Print, published online January 25, 2008 The Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial -- Revisited

More information

Glycemic Control Patterns and Kidney Disease Progression among Primary Care Patients with Diabetes Mellitus

Glycemic Control Patterns and Kidney Disease Progression among Primary Care Patients with Diabetes Mellitus ORIGINAL RESEARCH Glycemic Control Patterns and Kidney Disease Progression among Primary Care Patients with Diabetes Mellitus Doyle M. Cummings, PharmD, Lars C. Larsen, MD, Lisa Doherty, MD, MPH, C. Suzanne

More information

Randomized Controlled Clinical Trial of Glargine Versus Ultralente Insulin in the Treatment of Type 1 Diabetes

Randomized Controlled Clinical Trial of Glargine Versus Ultralente Insulin in the Treatment of Type 1 Diabetes Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Randomized Controlled Clinical Trial of Glargine Versus Ultralente Insulin in the Treatment of Type 1 Diabetes YOGISH C. KUDVA, MD, MBBS

More information

MANAGEMENT OF TYPE 1 DIABETES MELLITUS

MANAGEMENT OF TYPE 1 DIABETES MELLITUS MANAGEMENT OF TYPE 1 DIABETES MELLITUS INVESTIGATIONS AND TREATMENT MANSI NAIK VII SEMESTER INVESTIGATIONS FASTING BLOOD SUGAR PLASMA GLUCOSE HEMOGLOBIN A 1c SYMPTOMS OF TYPE 1 DIABETES MELLITUS Polyuria

More information

Blood glucose variations and cardiovascular risk in patients with diabetes

Blood glucose variations and cardiovascular risk in patients with diabetes Blood glucose variations and cardiovascular risk in patients with diabetes Thessaloniki 13 November 2009 Oliver Schnell, Executive Member of the Managing Board Diabetes Research Institute, Munich UKPDS

More information

Objectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment

Objectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Judy Thomas, MSN, FNP-BC Holt and Walton, Rheumatology and Endocrinology Objectives Upon completion of this session you will be better

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 57 Effective Health Care Program Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness Executive Summary Background Diabetes mellitus is

More information

New Guidelines for the Diagnosis of Diabetes Mellitus

New Guidelines for the Diagnosis of Diabetes Mellitus New Guidelines for the Diagnosis of Diabetes Mellitus Joely Straseski, PhD, DABCC, FACB Assistant Professor and Medical Director Endocrinology and Automated Core Laboratory University of Utah and ARUP

More information

Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study

Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study Diabetes Research and Clinical Practice 48 (2000) 201 210 www.elsevier.com/locate/diabres Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study

More information

DOI: /jemds/2014/2044 ORIGINAL ARTICLE

DOI: /jemds/2014/2044 ORIGINAL ARTICLE AN OBSERVATIONAL STUDY COMPARING SITAGLIPTIN TO METFORMIN AS A INITIAL MONOTHERAPY IN TYPE 2 DIABETES MELLITUS PATIENTS Mohd. Riyaz 1, Imran 2, Rinu Manuel 3, Nidhisha K. Joseph 4 HOW TO CITE THIS ARTICLE:

More information

Isolated Post-challenge Hyperglycemia: Concept and Clinical Significance

Isolated Post-challenge Hyperglycemia: Concept and Clinical Significance CLINICAL PRACTICE Isolated Post-challenge Hyperglycemia: Concept and Clinical Significance John MF. Adam*, Daniel Josten** ABSTRACT The American Diabetes Association has strongly recommended that fasting

More information

The snack is critical for the blood glucose profile during treatment with regular insulin preprandially

The snack is critical for the blood glucose profile during treatment with regular insulin preprandially Journal of Internal Medicine 1999; 245: 41 45 The snack is critical for the blood glucose profile during treatment with regular insulin preprandially A.-C. ORRE-PETTERSSON, T. LINDSTRÖM, V. BERGMARK &

More information

Metabolic Karma. - Essential Solution in Type2 DM - Eun Gyoung Hong, M.D., Ph.D

Metabolic Karma. - Essential Solution in Type2 DM - Eun Gyoung Hong, M.D., Ph.D 2014 ICDM Breakfast Symposium. Oct 18, 2014 Grand Hilton, Seoul Metabolic Karma - Essential Solution in Type2 DM - Eun Gyoung Hong, M.D., Ph.D Department of Endocrinology and Metabolism, Hallym University

More information

Julie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education

Julie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing

More information

Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta analysis

Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta analysis DOI 10.1186/s13098-016-0151-7 Diabetology & Metabolic Syndrome RESEARCH Open Access Lixisenatide improves glycemic outcomes of Japanese patients with type 2 diabetes: a meta analysis Hiroaki Seino 1*,

More information

These results are supplied for informational purposes only.

These results are supplied for informational purposes only. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information